<DOC>
	<DOCNO>NCT01333644</DOCNO>
	<brief_summary>It central hypothesis investigator study HIV disease pro-inflammatory condition , year inflammation result premature `` age ' immune system ( `` immunosenescence '' ) . Just change think causally associate heart disease old , investigator postulate change associate early heart disease untreated perhaps treat HIV disease . To address hypothesis , investigator measure immunosenescence large cohort patient span entire disease process .</brief_summary>
	<brief_title>The Role Inflammation Aging HIV-Associated Cardiovascular Risk</brief_title>
	<detailed_description />
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Inflammation</mesh_term>
	<mesh_term>Cardiovascular Diseases</mesh_term>
	<criteria>HIV controller : positive HIV standard antibody serological determination undetectable HIV RNA level ( &lt; 75 copy RNA/mL ) absence therapy HIV noncontrollers : detectable HIV RNA level absence therapy Highly active antiretroviral therapy responder ( HAART responder ) : combination antiretroviral therapy undetectable HIV RNA level . HIVseronegative participant also study . Treated individual change antiretroviral regimen within 12 week prior study enrollment . Individuals start stop antihypertensive medication lipid lower medication change dos drug within 12 week study exclude . As nitroglycerin administer assess endotheliumindependent vasodilation , also plan exclude patient take sildenafil , vardenafil , tadalafil within 72 hour endothelial function study , hypotensive ( systolic BP &lt; 100 ) .</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>May 2015</verification_date>
	<keyword>HIV Infection</keyword>
	<keyword>Endothelial function</keyword>
	<keyword>Cardiovascular Disease</keyword>
	<keyword>Inflammation</keyword>
	<keyword>Antiretroviral medication</keyword>
	<keyword>Treatment naive</keyword>
	<keyword>Treatment experience</keyword>
</DOC>